MA-GELSIGHT
12.10.2021 15:02:07 CEST | Business Wire | Press release
GelSight , a pioneer in tactile imaging and sensing technology, today introduced the latest version of its GelSight Mobile™ probe, the Series 2. This new generation of GelSight’s mobile device offers a sleek form-factor that is one-third lighter and less than half the volume of its predecessor, allowing it to scan surfaces in tighter spaces, while maintaining accuracy, speed, and field of view.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005405/en/
GelSight’s technology enables digital tactile sensing with the sensitivity and resolution of human touch. Data captured by GelSight’s elastomeric tactile sensing platform leverages proprietary software and algorithms to provide detailed, accurate surface characterization that can generate significant gains in productivity both on the production floor and in the field while also reducing the costs associated with manual or tool-based visual inspection. The handheld GelSight Mobile device can be deployed on production and assembly lines to enable rapid and well documented quality assurance decisions. Dimensions of scratches, dents, hits, gaps, offset, hole diameter, and fastener flushness can be measured in high-resolution, on any surface, in seconds.
The Series 2 head size has been minimized, so it can be utilized across a wider variety of applications. This is especially critical in the automotive and aerospace industries where it can provide rapid, repeatable, non-destructive testing for manufacturing and maintenance, repair, and overhaul (MRO) of engines, fuselages, and other critical components.
The Series 2 product addresses needs in new market verticals and creates new use cases as customers experience its game-changing performance first-hand. After bringing on new CEO, Youssef Benmokhtar, in June 2021, GelSight has set its sights on industries that can benefit from fast, accurate, micron-level measurements on a wide variety of surfaces, such as the additive manufacturing and energy sectors. The company will also continue to grow its core business in automotive, aerospace, and forensics.
“We took the accuracy, speed and mobility that our customers loved about the first-generation handheld device, and incorporated that into a smaller, more user-friendly form-factor that can deliver payback value in a matter of weeks in terms of saved production time, labor costs, and scrap,” said Youssef Benmokhtar, CEO, GelSight. “The introduction of Series 2 is ushering GelSight into a new era. We are digitizing tactile sensing to unlock new opportunities for in-line and off-line quality control innovation, across industries.”
“We use the GelSight Mobile for our MRO operations, and we are delighted to now incorporate the Mobile Series 2,” said Yann Siehen of Safran Helicopter Engines. “We had the opportunity to evaluate Series 2 and have been impressed by its performance. Its compact and lightweight design will definitely increase the number of use cases and will accelerate our return on investment.”
GelSight will be demoing the new device at the 2021 NBAA Business Aviation Convention & Exhibition (NBAA-BACE) October 12-14, 2021, in Las Vegas, NV at Booth #1224 – West Hall. To schedule a meeting and demo, please reach out to sales@gelsight.com .
The GelSight Mobile Series 2 is shipping now. To learn more about demo evaluations or purchasing, please email info@gelsight.com .
To learn more about GelSight, please visit https://gelsight.com/ .
About GelSight
GelSight develops portable, non-destructive elastomeric 3D imaging systems used to improve quality control processes in aerospace, automotive and other high-value industries. The proprietary technology that was invented at the Massachusetts Institute of Technology provides extremely detailed and rapid surface measurements and robotic sensing capabilities. For more information, please visit https://gelsight.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005405/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom